SFTPB and cancer: When the original risk score was analyzed as a continuous outcome in the benign (low and high) subgroup as well as the “low and cancer” subgroup, the common proteins between the two subgroups, SFTPB and CEACAM5, were added to AKR1B10 to explain the variation of the risk scores (Figure 7C).